UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/540,519	06/23/2005	Hideki Fujikura	Q88588	6623
SUGHRUE MION, PLLC 2100 PENNSYLVANIA AVENUE, N.W. SUITE 800 WASHINGTON, DC 20037			EXAMINER	
			MCINTOSH III, TRAVISS C	
			ART UNIT	PAPER NUMBER
			1623	
			MAIL DATE	DELIVERY MODE
			01/08/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/540,519	FUJIKURA ET AL.
Office Action Summary	Examiner	Art Unit
	TRAVISS C. MCINTOSH III	1623
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tinwill apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
1) ■ Responsive to communication(s) filed on 30 S 2a) ■ This action is FINAL . 2b) ■ This 3) ■ Since this application is in condition for alloward closed in accordance with the practice under B.	s action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 1-4,10,12-22 and 24-28 is/are pendir 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-4,10,12-22 and 24-28 is/are rejected 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	wn from consideration.	
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	cepted or b) objected to by the liderawing(s) be held in abeyance. See tion is required if the drawing(s) is objected.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate

DETAILED ACTION

The Amendment filed 9/30/2008 has been received, entered into the record, and carefully considered. The following information provided in the amendment affects the instant application by:

Claims 1, 2, 10, 13, and 22 have been amended.

Claims 25-28 have been added

Claims 5-9, 11, and 23 have been canceled.

Remarks drawn to rejections of Office Action mailed 3/31/2008 include:

Claim objections: which have been overcome by applicant's amendments and have been withdrawn.

112 2nd paragraph rejections: which have been overcome by applicant's amendments and have been withdrawn.

112 1st paragraph rejections: which have been overcome by applicant's amendments and have been withdrawn.

101 rejections: which have been overcome by applicant's amendments and have been withdrawn.

It is noted that applicant's have amended claim 1, on page 4, to overcome the previous $112\ 2^{nd}$ paragraph rejection. Upon further review, the examiner believes that the language used in the response filed 9/30/2008 would be better suited for the instant claims. Applicants noted that the language "and with the proviso that when ---; X^2 represents N or CR^2 (wherein R^2 represents

---); and when X⁴ represents N or CR⁴ (wherein R⁴ represents ---), R represents ---'' could be used.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Applicant cannot rely upon the foreign priority papers to overcome this rejection because a translation of said papers has not been made of record in accordance with 37 CFR 1.55. See MPEP § 201.15.

Claims 1-4, 10, 12-22, and 24-28 are rejected under 35 U.S.C. 102(a) as being anticipated by Nishimura et al. (WO03/000712).

Nishimura et al. disclose a species which anticipates the instant genus of compounds. See compound of example 6 for example, which is represented structurally by the formula:

Art Unit: 1623

wherein the instant variables are seen to be: X^1 is N; X^2 is CR^2 ; R^2 is G^5 and G^5 is methyl; X^3 and X^4 are each CH; R is a C_6 aryl group substituted by a $-G^3OG^4$ group; G^3 is an alkyl group; G^4 is an alkyl group substituted by OG^6 group; and G^6 is an alkyl group. It is noted that the methoxymethyloxyethyl group is not seen to be delimited by group Z of the proviso. Nishimura also teach their compounds are effective as SGLT2 inhibitors and effective for treating diseases associated with hyperglycemia such as diabetes.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to TRAVISS C. MCINTOSH III whose telephone number is (571)272-0657. The examiner can normally be reached on M-F 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/540,519 Page 5

Art Unit: 1623

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Traviss C McIntosh III/ Primary Examiner, Art Unit 1623 January 5, 2009